[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fujita Health University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100604627","thrombus-aspiration-and-pathology-and-oct-study-100604627",false,"NCT07151976","Thrombus Aspiration and Pathology and OCT Study","Pathologic Features of Aspirated Athero-Thrombotic Material From OCT-Verified Culprit Lesion in Acute Coronary Syndrome (TAPOS)","TAPOS","Inclusion Criteria:\n\n1. Patients with ACS showing ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) are studied.\n2. Only native coronary artery lesions are included in the study.\n3. Optical coherence tomography (OCT) was performed prospectively to compare OCT culprit lesions characteristics with histological analysis of athero-thrombotic aspirated material of the culprit lesion. For this purpose, only lesions with both athero-thrombotic aspirated material and OCT observations are included in the study.\n4. All patients provided written informed consent for the index procedure, follow-up, and anonymous data management.\n\nExclusion Criteria:\n\n1. Patients are excluded from the study when they had cardiogenic shock and contraindications to anticoagulation and anti-platelet therapy.\n2. Lesions located in tortuous vessels, in ostial segment and in the left main stem are excluded from the study due to the difficulty in performing high-quality intracoronary imaging.","ALL","20 Years",{"count":20,"type":21},200,"ESTIMATED","5 Years","OBSERVATIONAL","Most acute coronary syndromes (ACS) are caused by plaque complications triggering thrombotic events in the culprit plaques. Plaque complications include plaque rupture (Ruptured Fibrous Cap-RFC) with exposure of highly thrombogenic substrate to the flow and plaque erosion (Intact Fibrous Cap-IFC) a condition characterized by endothelial\u002Fintimal damage occurring over non-ruptured plaques. Far less commonly (\\\u003C5%), calcified nodules (CN) may trigger acute coronary thrombosis. Plaque rupture accounts for 75% of fatal AMI in autopsy series, while erosion is found in about 25% of cases. These proportions have been supported by in vivo invasive studies (OCT) and OCT-pathology correlation studies. However, it remains unclear whether OCT findings consistently align with in vivo pathology-based evidence of RFC in ACS. Guidelines addressing treatments of ACS unanimously indicate percutaneous coronary intervention (PCI) to restore the coronary flow. Pre-PCI thrombus aspiration is not currently indicated by most guidelines, with the exception of cases with very high thrombus burden. The samples retrieved from thrombus aspiration can be suitable for pathology investigation and aim to evaluate the presence of plaque components in the context of the thrombotic material, a finding that demonstrates plaque rupture as the substrate for the acute coronary event. These studies are uniquely qualified to provide information on the correct OCT-based interpretation of plaque complications in ACS and require OCT imaging quality suitable to classify RFC, IFC, and CN.\n\nTherefore, a prospective OCT-pathology study was designed using the pre-PCI aspirated material from patients with high thrombus burden, to explore the contribution of pathology study in OCT-based classification of plaque complications.",[26],"Acute Coronary Syndrome","RECRUITING","2026-02-03",{"date":30,"type":31},"2026-02-05","ACTUAL",{"date":33,"type":31},"2016-07-01",{"date":35,"type":21},"2027-12-31",{"name":37,"class":38},"Fujita Health University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":39},"100606048","phase-1-a-phase-ib-trial-of-combined-febuxostat-and-inosine-therapy-in-patients-with-parkinsons-disease-100606048","NCT07170475","A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease","iFRESH-PD","Inclusion Criteria:\n\n1. Able to provide voluntary written informed consent.\n2. Receiving stable Parkinson's disease medication (no changes in type or dose) for at least 3 months before enrollment.\n3. Age 18 to 80 years at the time of consent.\n4. Diagnosed with Parkinson's disease by a specialist according to MDS-PD diagnostic criteria, and at pre-enrollment screening, all of the following are met:\n\n   1. Hoehn-Yahr stage (ON state) 1 to 3\n   2. MDS-UPDRS Part III (ON state) score 10 to 35\n   3. Mini-Mental State Examination (MMSE) score ≥ 24\n\nExclusion Criteria:\n\n1. Requires almost total assistance in daily life and is unable to walk or stand unaided.\n2. Currently taking azathioprine, mercaptopurine hydrate, vidarabine, didanosine, or rosuvastatin.\n3. Used febuxostat, allopurinol, or topiroxostat within 3 months before study start.\n4. Taking any supplement containing inosine.\n5. Started any new Parkinson's disease medication or therapy within 3 months before enrollment.\n6. Serum creatinine \\>1.5× upper limit of normal (ULN), or AST (GOT) or ALT (GPT) \\>2× ULN at screening.\n7. History of surgical treatment for Parkinson's disease.\n8. History of or comorbid hypersensitivity\u002Fallergy to any ingredient of the investigational drugs.\n9. Participation in another clinical trial involving an unapproved drug within 30 days before consent, or currently enrolled in another interventional study.\n10. Pregnant or breastfeeding, or unwilling\u002Funable to use reliable contraception during the study period.\n11. Positive test at screening for HIV, HBV, HTLV-1, or syphilis; \\*\\*HCV antibody-positive with undetectable HCV RNA\\*\\* is allowed.\n12. Unable to take the investigational drugs orally without changing the dosage form.\n13. Gastrointestinal disease or prior GI surgery that may affect drug absorption, as judged by the investigator.\n14. Psychiatric disorder or symptoms that interfere with daily life and make study participation difficult.\n15. Unable to complete assessments or questionnaires independently.\n16. Any other condition that, in the investigator's judgment, would make participation unsafe or inappropriate.","18 Years","80 Years",{"count":50,"type":21},24,"INTERVENTIONAL",[53],"PHASE1","This study will test the safety of twice-daily oral dosing of combined febuxostat and inosine in 24 patients with Parkinson's disease. Participants will receive one of the four regimens, taken twice daily for 12 weeks:\n\nWho can join: Adults with early-stage Parkinson's disease on stable medication regimens.\n\nWhat participants do:\n\n* Take their assigned dose twice daily (morning and evening) for 12 weeks.\n* Visit the clinic at baseline and weeks 4, 8, and 12 for blood tests (including hypoxanthine), exams, and questionnaires.\n* Keep a simple diary of any side effects or changes in daily activities.\n\nRisks and benefits: Possible side effects include mild gastrointestinal upset, headache, or elevated uric acid levels. While direct benefit is not guaranteed, this safety data will inform future Parkinson's disease treatments.\n\nLearn more: Contact \\[site-specific contact info\\] for details on eligibility and enrollment.",[56],"Parkinson's Disease (PD)",[58,59,60,61,62,63],"Parkinson Disease","Febuxostat","Inosine","Hypoxanthine","Combination Therapy","Safety Study","2025-09-07",{"date":66,"type":31},"2025-09-12",{"date":68,"type":31},"2025-06-27",{"date":70,"type":21},"2026-07-31",{"name":37,"class":38},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":39},"100555177","ct-angiography-plaque-characteristics-and-events-in-deferral-patients-by-invasive-fractional-flow-reserve-100555177","NCT06508697","CT-Angiography Plaque Characteristics and Events in Deferral Patients by Invasive Fractional Flow Reserve","CT-Angiography-Derived Plaque Characteristics on Cardiac Events in Deferral Patients by Invasive Fractional Flow Reserve","CAPTURE","Inclusion Criteria:\n\n* men and women aged ≥20 years,\n* patients having chronic coronary syndromes (CCS,\n* Coronary computed tomography angiography (CTA) was performed within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement.\n\nExclusion Criteria:\n\n* patients with a history of coronary bypass grafting (CABG) because CABG changed local coronary flow dynamics,\n* patients with left-main disease,\n* patients with fractional flow reserve (FFR) in stented vessels due to inability to estimate plaque morphology in the stented lesion by coronary computed tomography angiography.",{"count":81,"type":21},400,"3 Years","Fractional flow reserve (FFR)-guided PCI for chronic coronary syndromes (CCS) is reported to improve the outcomes compared with angiography-guided PCI. However, cardiac-events still occur in FFR-deferral patients in long-term follow-up. Coronary computed tomography angiography (CTA)-defined high-risk-plaque (HRP) is known to relate future cardiac events. The investigators hypothesized that CTA might identify plaque features linked to future cardiac events in deferral patients.",[85],"Patient Preference","2025-01-02",{"date":88,"type":31},"2025-01-03",{"date":90,"type":21},"2025-01-30",{"date":92,"type":21},"2026-12-31",{"name":37,"class":38},""]